Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials

BIOXYTRAN, INC

Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.
Net proceeds of $576,000 after 4% placement agent fee paid to WallachBeth Capital.
Proceeds intended for down-payment on human trials of ProLectin-M (oral) for Covid-19 and ProLectin-I (IV) for lung fibrosis.
Shares offered on best-efforts basis; no minimum offering amount; funds available immediately upon acceptance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.